Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individually Adapted Therapy Duration for Chronic Hepatitis C Genotype 1
NCT00351403Phase 4Completed
- Sponsor
- FGK Clinical Research
- Start
- Jul 2006
- Primary completion
- Jan 2010
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C (HCV) (2 arms), sponsored by FGK Clinical Research. Primary endpoint: Sustained Viral Response. Started Jul 2006; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00351403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00351403.